Use of Thiazolidinediones and the Risk of Colorectal Cancer in Patients With Diabetes
Open accessThe DOI matches its Crossref record; 28 of the 28 references it cites were found in a registry or an index.
Abstract
OBJECTIVE: Preclinical data suggest that peroxisome proliferator–activated receptor γ (PPARγ) agonists have antineoplastic effects in colorectal cancer. We aimed to assess the association between the use of synthetic PPARγ agonists, represented by thiazolidinediones (TZDs), and the risk of developing colorectal cancer. RESEARCH DESIGN AND METHODS: We conducted a nationwide, population-based, case-control study using the Taiwan National Health Insurance Research Database. Case subjects were defined as patients who were diagnosed with diabetes at least 365 days prior to a new diagnosis of colorectal cancer between 2000 and 2008. We randomly selected diabetic control subjects for each case subject, which were matched by sex, age, and the duration of diabetes. Among the 24,496 eligible case subjects and control subjects, we used conditional logistic regression to assess the risk of colorectal cancer in association with the use of TZDs. An additional analysis was conducted to assess the effects of concomitant use of TZDs and low-dose aspirin or nonsteroidal anti-inflammatory drugs (NSAIDs) on the risk of colorectal cancer. RESULTS: A decreased risk of colorectal cancer was observed in patients who had used TZDs compared with those who had never used TZDs (adjusted odds ratio 0.86 [95% CI 0.79–0.94]). Furthermore, the benefit of a decreased colorectal cancer risk was also found with concomitant use of TZDs and low-dose aspirin or NSAIDs. CONCLUSIONS: The use of TZDs may be associated with a decreased risk of colorectal cancer in patients with diabetes. Further studies are warranted to confirm our findings.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures

Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“Other research suggests that PPAR-γ agonists might prevent certain cancers.50,51”
From Pioglitazone after Ischemic Stroke or Transient Ischemic Attack (2016) · cites this paper as [51]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The nuclear receptor superfamily: the second decade
Mangelsdorf, D. J., Thummel, C., Beato, M., Herrlich, P., Schütz, G., Umesono, K., Blumberg, B., Kastner, P., Mark, M., Chambon, P., et al. (1995) · Cell · doi:10.1016/0092-8674(95)90199-x · Cited by 6,964 · cited 1×
“The PPARs are ligand-activated transcription factors that modulate gene expression (1,2).”
Background15-Deoxy-Δ12,14-Prostaglandin J2 is a ligand for the adipocyte determination factor PPARγ
Forman, B. M., Tontonoz, P., Chen, J., Brun, R. P., Spiegelman, B. M., & Evans, R. M. (1995) · Cell · doi:10.1016/0092-8674(95)90193-0 · Cited by 2,858
Self-citationDiabetes Mellitus, Fasting Glucose, and Risk of Cause-Specific Death
The Emerging Risk Factors Collaboration (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1008862 · Cited by 2,726
Giovannucci, E., Harlan, D. M., Archer, M. C., Bergenstal, R. M., Gapstur, S. M., Habel, L. A., Pollak, M., Regensteiner, J. G., & Yee, D. (2010) · Diabetes Care · doi:10.2337/dc10-0666 · Cited by 2,366 · cited 1×
“Appropriately, glucose control plays a role in effective diabetes management, which may lessen morbidity and mortality by reducing the risk of diabetes-associated complications (30).”
BackgroundRoles of PPARs in health and disease
Kersten, S., Desvergne, B., & Wahli, W. (2000) · Nature · doi:10.1038/35013000 · Cited by 1,956 · cited 1×
“The PPARs are ligand-activated transcription factors that modulate gene expression (1,2).”
BackgroundRothwell, P. M., Wilson, M., Elwin, C.-E., Norrving, B., Algra, A., Warlow, C. P., & Meade, T. W. (2010) · The Lancet · doi:10.1016/s0140-6736(10)61543-7 · Cited by 1,351 · cited 1×
“Low-dose aspirin was widely recommended for the primary prevention of cardiovascular events in patients with diabetes, and it has been suggested to reduce incidence and mortality due to colorectal cancer (24,25).”
BackgroundDifferentiation and reversal of malignant changes in colon cancer through PPARγ
Sarraf, P., Mueller, E., Jones, D., King, F. J., DeAngelo, D. J., Partridge, J. B., Holden, S. A., Chen, L. B., Singer, S., Fletcher, C., et al. (1998) · Nature Medicine · doi:10.1038/2030 · Cited by 988 · cited 2×
“PPARg is activated by several natural and synthetic ligands, and its activation elicits cell differentiation and induces cell cycle arrest and apoptosis (3,4).”
BackgroundFlossmann, E., & Rothwell, P. M. (2007) · The Lancet · doi:10.1016/s0140-6736(07)60747-8 · Cited by 820
Risk of Bladder Cancer Among Diabetic Patients Treated With Pioglitazone
Lewis, J. D., Ferrara, A., Peng, T., Hedderson, M., Bilker, W. B., Quesenberry, C. P., Vaughn, D. J., Nessel, L., Selby, J., & Strom, B. L. (2011) · Diabetes Care · doi:10.2337/dc10-1068 · Cited by 625
Does Universal Health Insurance Make Health Care Unaffordable? Lessons From Taiwan
Lu, J.-F. R., & Hsiao, W. C. (2003) · Health Affairs · doi:10.1377/hlthaff.22.3.77 · Cited by 529 · cited 1×
“According to the NHI Act, false reports of diagnosis or inappropriateness of medical services will yield a severe penalty (17,19).”
BackgroundXin, X., Yang, S., Kowalski, J., & Gerritsen, M. E. (1999) · Journal of Biological Chemistry · doi:10.1074/jbc.274.13.9116 · Cited by 513
Antineoplastic effects of peroxisome proliferatoractivated receptor γ agonists
Grommes, C., Landreth, G. E., & Heneka, M. T. (2004) · The Lancet Oncology · doi:10.1016/s1470-2045(04)01509-8 · Cited by 440
Rostom, A., Dubé, C., Lewin, G., Tsertsvadze, A., Barrowman, N., Code, C., Sampson, M., & Moher, D. (2007) · Annals of Internal Medicine · doi:10.7326/0003-4819-146-5-200703060-00010 · Cited by 343
Thiazolidinediones and the risk of lung, prostate, and colon cancer in patients with diabetes
Govindarajan, R., Ratnasinghe, L., Simmons, D. L., Siegel, E. R., Midathada, M. V., Kim, L., Kim, P. J., Owens, R. J., & Lang, N. P. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.07.2777 · Cited by 336 · cited 4×
“(11) suggested that the use of TZDs was associated with a reduced risk for colon cancer among male African American patients but not among white patients.”
BackgroundMethodInfluentialTanaka, T., Kohno, H., Yoshitani, S., Takashima, S., Okumura, A., Murakami, A., & Hosokawa, M. (2001) · PubMed · Cited by 290
PPARγ ligands inhibit primary tumor growth and metastasis by inhibiting angiogenesis
Panigrahy, D., Singer, S., Shen, L. Q., Butterfield, C. E., Freedman, D. A., Chen, E. J., Moses, M. A., Kilroy, S., Duensing, S., Fletcher, C., et al. (2002) · Journal of Clinical Investigation · doi:10.1172/jci0215634 · Cited by 276
Smalley, W., Ray, W. A., Daugherty, J., & Griffin, M. R. (1999) · Archives of Internal Medicine · doi:10.1001/archinte.159.2.161 · Cited by 264
Taiwan's 1995 health care reform
Chiang, T.-L. (1997) · Health Policy · doi:10.1016/s0168-8510(96)00877-9 · Cited by 259 · cited 1×
“48% of the entire Taiwanese population was enrolled in this program (17,18).”
BackgroundThe nuclear eicosanoid receptor, PPARgamma, is aberrantly expressed in colonic cancers
DuBois, R. (1998) · Carcinogenesis · doi:10.1093/carcin/19.1.49 · Cited by 255
Expression of the Peroxisome Proliferator-Activated Receptor (PPAR) in the Mouse Colonic Mucosa
Mansén, A., Guardiola-Diaz, H., Rafter, J., Branting, C., & Gustafsson, J.-Å. (1996) · Biochemical and Biophysical Research Communications · doi:10.1006/bbrc.1996.0832 · Cited by 217
Osawa, E., Nakajima, A., Wada, K., Ishimine, S., Fujisawa, N., Kawamori, T., Matsuhashi, N., Kadowaki, T., Ochiai, M., Sekihara, H., et al. (2003) · Gastroenterology · doi:10.1053/gast.2003.50067 · Cited by 196
Cohort Study of Pioglitazone and Cancer Incidence in Patients With Diabetes
Ferrara, A., Lewis, J. D., Quesenberry, C. P., Peng, T., Strom, B. L., Van Den Eeden, S. K., Ehrlich, S. F., & Habel, L. A. (2011) · Diabetes Care · doi:10.2337/dc10-1067 · Cited by 181 · cited 2×
“We searched the PubMed database for articles published up to July 2011 and identified three original clinical studies focusing on the assessment of cancer risks, including colorectal cancer, in patients exposed to TZDs (11,12,14).”
MethodNon-Steroidal Anti-Inflammatory Drugs and Colorectal Cancer Risk in a Large, Prospective Cohort
Ruder, E. H., Laiyemo, A. O., Graubard, B. I., Hollenbeck, A. R., Schatzkin, A. G., & Cross, A. J. (2011) · The American Journal of Gastroenterology · doi:10.1038/ajg.2011.38 · Cited by 154
Kulke, M. H., Demetri, G. D., Sharpless, N. E., Ryan, D. P., Shivdasani, R., Clark, J. S., Spiegelman, B. M., Kim, H., Mayer, R. J., & Fuchs, C. S. (2002) · The Cancer Journal · doi:10.1097/00130404-200209000-00010 · Cited by 150
Thiazolidinediones as anti-cancer agents.
Blanquicett, C., Roman, J., & Hart, C. M. (2008) · PubMed · Cited by 146
Cancer risks in thiazolidinedione users compared to other anti-diabetic agents
Koro, C., Barrett, S., & Qizilbash, N. (2007) · Pharmacoepidemiology and Drug Safety · doi:10.1002/pds.1352 · Cited by 107 · cited 2×
“We searched the PubMed database for articles published up to July 2011 and identified three original clinical studies focusing on the assessment of cancer risks, including colorectal cancer, in patients exposed to TZDs (11,12,14).”
BackgroundMethodRosiglitazone and Risk of Cancer
Monami, M., Lamanna, C., Marchionni, N., & Mannucci, E. (2008) · Diabetes Care · doi:10.2337/dc07-2308 · Cited by 97
Lewis, J. D., Capra, A. M., Achacoso, N. S., Ferrara, A., Levin, T. R., Quesenberry, C. P., & Habel, L. A. (2008) · Gastroenterology · doi:10.1053/j.gastro.2008.09.004 · Cited by 24
Cited by
Pioglitazone after Ischemic Stroke or Transient Ischemic Attack
Kernan, W. N., Viscoli, C. M., Furie, K. L., Young, L. H., Inzucchi, S. E., Gorman, M., Guarino, P. D., Lovejoy, A. M., Peduzzi, P. N., Conwit, R., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1506930 · Cited by 1,124
Chang, S.-H., Wu, L.-S., Chiou, M.-J., Liu, J.-R., Yu, K.-H., Kuo, C.-F., Wen, M.-S., Chen, W.-J., Yeh, Y.-H., & See, L.-C. (2014) · Cardiovascular Diabetology · doi:10.1186/s12933-014-0123-x · Cited by 225
Diabetes and cancer: Pathophysiological fundamentals of a ‘dangerous affair’
Cignarelli, A., Genchi, V. A., Caruso, I., Natalicchio, A., Perrini, S., Laviola, L., & Giorgino, F. (2018) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2018.04.002 · Cited by 161
Diabetes and Colorectal Cancer Risk: Clinical and Therapeutic Implications
Yu, G., Li, S.-F., Wei, R., & Jiang, Z. (2022) · Journal of Diabetes Research · doi:10.1155/2022/1747326 · Cited by 123
Do We Still Need Pioglitazone for the Treatment of Type 2 Diabetes? A risk-benefit critique in 2013
Schernthaner, G., Currie, C. J., & Schernthaner, G.-H. (2013) · Diabetes Care · doi:10.2337/dcs13-2031 · Cited by 100
Metadata
- Authors
- Chen, S.-W., Tsan, Y.-T., Chen, J.-D., Hsieh, H.-I., Lee, C.-H., Lin, H.-H., Wang, J.-D., Chen, P.-C., & Health Data Analysis in Taiwan Research Group
- Affiliations
- National Taiwan University (TW)
- Fu Jen Catholic University (TW)
- National Cheng Kung University (TW)
- Corresponding author
- Chen, Pau-Chung
- Venue
- Diabetes Care
- Publisher
- American Diabetes Association
- Published
- 2013-01-17
- Volume
- 36
- Issue
- 2
- Pages
- 369-375
- ISSN
- 0149-5992 (ISSN-L)
- 1935-5548
- PMC
- PMC3554275
- OpenAlex
- W2098056191
- Cited by
- 37
- References
- 28
- Citations by year
- 2026: 1 · 2025: 2 · 2024: 2 · 2023: 2 · 2022: 1 · 2021: 5 · 2020: 2 · 2019: 2 · 2018: 2 · 2017: 1 · 2016: 3 · 2015: 3 · 2014: 6 · 2013: 4
- FWCI
- 1.56
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- Diabetes Care (publishedVersion, cc-by-nc-nd)
- Europe PMC (PubMed Central) (publishedVersion, cc-by-nc-nd)
- PubMed Central (publishedVersion, cc-by-nc-nd)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Peroxisome Proliferator-Activated Receptors
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Metabolism, Diabetes, and Cancer
- Health Sciences › Medicine › Oncology › Colorectal Cancer Screening and Detection
- Keywords
- thiazolidinediones, colorectal cancer, diabetes mellitus, PPARγ agonists, cancer risk, aspirin, nonsteroidal anti-inflammatory drugs, chemoprevention
- MeSH terms
- Adult, Aged, Diabetes Mellitus, Type 2, Female, Humans, Male, Middle Aged, Colorectal Neoplasms, Case-Control Studies, Thiazolidinediones
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.